PMID- 29788955
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20221207
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 17
IP  - 1
DP  - 2018 May 22
TI  - Effect of canagliflozin on left ventricular diastolic function in patients with 
      type 2 diabetes.
PG  - 73
LID - 10.1186/s12933-018-0717-9 [doi]
LID - 73
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) greatly increases the risks of 
      cardiovascular disease and heart failure. In particular, left ventricular 
      diastolic dysfunction that develops from the early stages of T2DM is an important 
      factor in the onset and exacerbation of heart failure. The effect of 
      sodium-glucose cotransporter 2 inhibitors on left ventricular diastolic function 
      has not been elucidated. We have performed the first prospective study on the 
      effects of canagliflozin on left ventricular diastolic function in T2DM. METHODS: 
      This study was performed to evaluate the effects of additional treatment with 
      canagliflozin for 3 months on left ventricular diastolic function in patients 
      with T2DM. A total of 38 patients with T2DM were consecutively recruited for this 
      study. Left ventricular diastolic function was assessed by echocardiography. The 
      primary study outcome was a change in the septal E/e' as a parameter of left 
      ventricular diastolic function. RESULTS: A total of 37 patients (25 males and 12 
      females) were included in the analysis. Mean age of participants was 
      64.2 +/- 8.1 years (mean +/- SD), mean duration of diabetes was 13.5 +/- 8.1 years, and 
      mean HbA1c was 7.9 +/- 0.7%. Of the participants, 86.5% had hypertension, 100% had 
      dyslipidemia, and 32.4% had cardiovascular disease. Canagliflozin significantly 
      improved left ventricular diastolic function (septal E/e' ratio 
      13.7 +/- 3.5-12.1 +/- 2.8, p = 0.001). Furthermore, among the various parameters that 
      changed through the administration of canagliflozin, only changes in hemoglobin 
      significantly correlated with changes in the septal E/e' ratio (p = 0.002). In 
      multiple regression analysis, changes in hemoglobin were also revealed to be an 
      independent predictive factor for changes in the septal E/e' ratio. CONCLUSIONS: 
      This study showed for the first time that canagliflozin could improve left 
      ventricular diastolic function within 3 months in patients with T2DM. The benefit 
      was especially apparent in patients with substantially improved hemoglobin 
      values. Trial registration UMIN Clinical Trials Registry UMIN000028141.
FAU - Matsutani, Daisuke
AU  - Matsutani D
AD  - Division of Diabetes, Metabolism and Endocrinology, Department of Internal 
      Medicine, Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, 
      Minato-ku, Tokyo, 105-8461, Japan.
FAU - Sakamoto, Masaya
AU  - Sakamoto M
AUID- ORCID: 0000-0001-7839-0780
AD  - Division of Diabetes, Metabolism and Endocrinology, Department of Internal 
      Medicine, Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, 
      Minato-ku, Tokyo, 105-8461, Japan. m-sakamoto@umin.ac.jp.
FAU - Kayama, Yosuke
AU  - Kayama Y
AD  - Department of Cardiology, Jikei University School of Medicine, 3-25-8, 
      Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
FAU - Takeda, Norihiko
AU  - Takeda N
AD  - Department of Cardiovascular Medicine, Graduate School of Medicine, The 
      University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8654, Japan.
FAU - Horiuchi, Ryuzo
AU  - Horiuchi R
AD  - Department of Pathology, Tsuruoka Kyoritsu Hospital, 9-34, Fumizonomachi, 
      Tsuruoka-shi, Yamagata, 997-0816, Japan.
FAU - Utsunomiya, Kazunori
AU  - Utsunomiya K
AD  - Division of Diabetes, Metabolism and Endocrinology, Department of Internal 
      Medicine, Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, 
      Minato-ku, Tokyo, 105-8461, Japan.
LA  - eng
SI  - UMIN-CTR/UMIN000028141
PT  - Journal Article
PT  - Observational Study
DEP - 20180522
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Blood Glucose/drug effects/metabolism
MH  - Canagliflozin/*therapeutic use
MH  - Diabetes Mellitus, Type 2/blood/complications/diagnosis/*drug therapy
MH  - Diabetic Cardiomyopathies/diagnostic imaging/*drug 
      therapy/etiology/physiopathology
MH  - Diastole
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Recovery of Function
MH  - Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/diagnostic imaging/*drug 
      therapy/etiology/physiopathology
MH  - Ventricular Function, Left/*drug effects
PMC - PMC5963148
OTO - NOTNLM
OT  - Autonomic function
OT  - Heart failure with preserved ejection fraction
OT  - Left ventricular diastolic function
OT  - Sodium-glucose cotransporter 2 inhibitors
OT  - Type 2 diabetes mellitus
EDAT- 2018/05/24 06:00
MHDA- 2019/01/29 06:00
PMCR- 2018/05/22
CRDT- 2018/05/24 06:00
PHST- 2018/03/21 00:00 [received]
PHST- 2018/05/17 00:00 [accepted]
PHST- 2018/05/24 06:00 [entrez]
PHST- 2018/05/24 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/05/22 00:00 [pmc-release]
AID - 10.1186/s12933-018-0717-9 [pii]
AID - 717 [pii]
AID - 10.1186/s12933-018-0717-9 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2018 May 22;17(1):73. doi: 10.1186/s12933-018-0717-9.